Ultragenyx Pharmaceutical
Clinical-stage biotechnology company focused on debilitating metabolic genetic diseases.
Based in CA
AI Overview
With $325K in lobbying spend across 11 quarterly filings, Ultragenyx Pharmaceutical is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2019 to 2022.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $0 |
| 2020 | $130K |
| 2021 | $195K |
| 2022 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Ultragenyx Pharmaceutical disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues
Drug Pricing and Innovation
H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
S.2543 - Prescription Drug Pricing Reduction Act of 2019
Drug pricing and innovation
H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act
S.2543 - Prescription Drug Pricing Reduction Act of 2019
New Born Screening, Orphan Drug Act, FDA
New Born Screening Act, Drug Pricing, Priority Review Voucher Program
Drug pricing
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.